Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy

详细信息    查看全文

• 作者：Wennan Zhao^&dagger ; ; Yuling Qiu^&dagger ; ; Dexin Kong ; ^{kongdexin@tmu.edu.cn}
• 关键词：Phosphatidylinositol 3-kinase ; PI3K inhibitor ; Drug candidate ; Cancer therapy ; PI3K/mTOR selectivity ; Anticancer
• 刊名：Acta Pharmaceutica Sinica B
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：7
• 期：1
• 页码：27-37
• 全文大小：2983 K
• 卷排序：7

文摘

The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers. Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis. Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors. Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy. Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials. Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc. This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.